Background: The molecular recognition theory (MRT) provides a conceptual framework that could explain the evolution of intermolecular and intramolecular interaction of peptides and proteins. As such, it predicts that binding sites of peptide hormones, and its receptor binding sites were originally encoded by and evolved from complementary strands of genomic DNA. Materials and Methods: On the basis of principles underlying the MRT, we screened a rat brain comple-
Introduction
The hydropathic character of an amino acid appears to be determined by the second base of a particular codon (1) . A second base, U, generally specifies hydrophobic amino acids, while a second base, A, specifies hydrophilic amino acids (1) . Since Numerous biochemical studies have reported experimental evidence in support of this theory (4, 5) . However, the molecular recognition theory still remains controversial because of some negative biochemical and theoretical analysis (6) (7) (8) (9) (10) . Our recent report identifying the AngII/AVP receptor represents the first molecular genetic evidence in support of this theory (11) . Our current studies were designed to further test this theory by screening a rat brain complementary DNA library using an AngIl followed by an endothelin-1 (ET-1) antisense oligonucleotide probe to potentially isolate additional AngIl and ET-I receptor isoforms. As with the AngII/AVP receptor (11) , an identical cDNA clone was isolated independently from both the AnglI and ET-1 oligonucleotide screenings. Functional and mutational studies of the predicted polypeptide elucidates a novel dual ET-l/ AngII receptor, providing further molecular genetic evidence in support of the molecular recognition theory, as well as demonstrating for the first time a molecular link between the ET-I and AngII hormonal systems. The identification of the structural determinants of hormone binding within the dual ET-1 /AngII receptor provides new insight into the evolutionary origin of hormone-binding domains present in different isoreceptors.
Materials and Methods cDNA Screening and Nucleotide Sequencing
An adult rat brain AgtI 1 cDNA library (Clontech) was screened twice independently with the ET-I [5'-CCAGATGATGTCCAGGTGGCAGAAGTAGA CACACTCTTTATCCATCAGGGAAGAGCAGGAG CA-3'] (12) and AnglI [5'-AAAGGGGTGGATGT ATACGCGGTC-3'] (13) antisense oligonucleotide probes. Hybridizations were done as described (11) . After the first round of hybridization, a significant number of potential positive signals were detected. Of these, we proceeded to isolate five cDNA clones hybridizing to the AngIl probe and three cDNA clones hybridizing to the ET-1 probe. These clones showed the greatest signal to background ratio and they represented less than 5 % of the potential positive signals. Among these clones we detected the 3.3-kb cDNA isolated in both AnglI and ET-1 screenings. The 3.3-kb cDNAs were subcloned into M1 3 vectors and subsequently sequenced on both strands as described elsewhere (11) . DNA sequence analysis was done using the GENEPRO computer DNA analysis program (Riverside Scientific Enterprises).
Expression Studies in CoslpMAM-ET-1/AngII Transfectants The 756-bp SspI-EcoRI fragment spanning nucleotides 2518-3274 of the full-length ET-i/AngII receptor cDNA was subcloned directionally (5'-3') into the NheI site of the pMAMneo expression vector (Clontech). The pMAM-ET-i/ AngII expression vector was then transfected into Cosl cells and stable transfectants were selected and maintained in G418 for subsequent studies. Expression of mutant receptors was done similarly using the pMAM-ET-1 /AngII R64G and pMAM-ET-1 /AngII W65G expression vectors. 45Ca2+ efflux assays were done essentially as previously described (14) . Cell cultures (P 35 dishes) were equilibrated with 45Ca2+ under standard growth conditions (DMEM + 10% FCS + 250 ,ug/ml G418 + 5 ,Ci/ml of 45CaC12) for 18 to 20 hr. Assays were initiated by removal of the 45Ca21 media and followed by rapid sequential washing and aspirations with three 1 -ml aliquots of physiological buffer (PB composition in mmol/L: NaCl 140; KCI 5.4; CaCl2 1.8; MgCl2 1.6; D-glucose 5.5; Hepes 5, pH 7.4). One milliliter of assay solution containing appropriate ligands dissolved in PB were promptly added and efflux was allowed to proceed for the specific time intervals. Efflux was terminated by rapid washing and aspiration with three 1 -ml aliquots of MgCl2-free PB containing 5 (Fig. 1C) , and G41AASMQV47 as a potential AngII binding domain (Fig. 1 C) within the ET-i /AngII receptor. This analysis also delineates the antisense peptide from frame 2 as the putative evolutionary ET-1 precursor binding domain (Fig. IC) , whereas the antisense peptide from frame 3 is the putative evolutionary AnglI precursor binding domain (Fig. 1C) . Consistently, the single region with the highest nucleotide sequence homology to the AngII oligonucleotide probe (63% identity spanning nucleotides [nt] 2802-2820) and the single region with the highest nucleotide sequence homology to the ET-1 oligonucleotide probe (65% identity spanning nt 2859-2881) are distinct and correspond to the AngII and ET-I antisense peptide homology regions (Fig. 1 ). According to the molecular recognition theory, these antisense homology regions should identify putative AngII and ET-I binding domains, respectively.
Hydropathy analysis using the KyteDoolittle scale (15) and GES hydropathy plot (16) predicts a single transmembrane domain (H-1; Fig. IA ). H-I (n = 20 amino acids) is predicted to cross the plasma membrane considering that a transmembrane region of 12-14 amino acids have been experimentally proven to be sufficient to cross the plasma membrane (17) . The existence of a single transmembrane-spanning region in conjunction with the identification of the putative AngII and ET-I binding domains within the amino terminal end predict the localization of the ET-I /AngII receptor amino terminal end to the extracellular side (Fig. 1B) dependent protein kinase, Sq9 and T108 (18, 19) , can be noted in the predicted cytoplasmic carboxyl-end (Fig. 1) . A potential internalization recognition sequence (IRS) is also found in the cytoplasmic carboxyl-end: Y111RRP,14 ( Fig. 1 (Fig. 1) . Con- (Fig. 2A, B) . Measured as the % 45Ca2+ efflux activity indicated by % 45Ca2+ retained (14) , 100 nmol/L ET-I and 100 nmol/L AngIl elicited equivalent amounts of Ca21 mobilization (Fig. 2B) . No responses were elicited by either arginine-vasopressin (AVP) or bradykinin. In comparison to ET-1, ET-2 induced 60% 45Ca2+ efflux activity, whereas ET-3 induced none at all. Similarly, compared with AngIl, AngIlI induced 25 % 45Ca2 + efflux activity, whereas AngI induced none at all (Fig. 2B) . The effects of antagonists on the ET-I /AngII receptor were also analyzed. An AnglI-specific antagonist (Sarl, Ala8-AngII) efficiently blocked both AngIland ET-I-induced 45Ca2+ efflux (Fig. 2B) . This is consistent with the notion that AngIl-and ET-Iinduced responses were mediated by the same receptor.
The specificities of the ET-I and AngIl responses of the dual ET-i /AngII receptor were then assessed in concentration dependence as- (Fig. 1) as previously described (41) . Nondegradation of RNA samples and relative amounts are directly documented in the ethidium-bromide picture presented in parallel (B). 28S and 18S ribosomal RNAs are marked by arrowheads.
says measuring ET-1-and AnglI-induced 45Ca2+ efflux. The response to both ET-I and AngIl were similar with equivalent effector concentration for half-maximal response (EC50) values of 7 ± 1.4 pmol/L (Fig. 2C) and 6 + 0.9 pmol/L (Fig. 2D) , respectively. Pharmacologic specificity was further ascertained by ligand dissociation studies. As shown in Fig. 2E and F, high (KH) and low (I(L) affinity sites were detected for both ET-I and AnglI with KH (Fig. 2E, F) . Displacement of ET-1 by ET-2 was also detected with high-and low-affinity sites with a KiH of 1 ± 0.13 nmol/L and KiL of 300 + 33 nmol/L (Fig. 2E) . In contrast, displayed a single low-affinity site with a KiL of 20 ± 1.6 nmol/L (Fig. 2E) . Displacement of AngIl by the AT1 receptor-specific antagonist, Losartan, was detected with a KiH of 0.7 ± 0.14 nmol/L and KiL of 160 ± 19 nmol/L (Fig. 2F) . The AT2-specific antagonist, PD123319, did not displace AngIl binding up to concentrations of mol/L (Fig. 2F) . These results define the ET-l/ AngIl receptor as a novel AT1 receptor isoform coupled to Ca21-mobilizing pathways.
Immunocytochemical Localization of the ET-i1/AngII
Receptor In order to ascertain the cytolocalization and predicted topography of the ET-i /AngII receptor polypeptide, immunocytochemical studies were done on intact (nonpermeabilized) CosIpMAM-ET-i /AngII transfectants utilizing a polyclonal antipeptide antibody raised against amino acids 51-60 of the predicted extracellular domain (Fig. 1) . As shown in Fig. 3 , prominent staining was observed in pMAM-ET-1 /AngII transfectants (Fig. 3B) . In contrast, the cells transfected with the parental expression vector, CoslpMAMneo, were not stained (Fig. 3A) . These results corroborate the predicted topography and cell membrane localization of the ET-I/ AnglI receptor.
Tissue Distribution of the ET-1lAngII Receptor mRNA Analysis of the ET-I /AngII receptor mRNA tissue distribution by Northern blot analysis (Fig. 4) revealed an approximately 4-kb mRNA prominently expressed in brain and heart tissues. Much lower but detectable levels can be observed in aorta, adrenal gland, and lung tissues. Northern analysis did not detect ET-i /AngII receptor sequences in kidney and liver. However, reverse transcriptase-polymerase chain amplification of 5' untranslated RNA sequences could detect the ET-I /AngII mRNA in all tissues tested, including kidney and liver (data not shown).
Site-Directed Mutagenesis of the ET-1 Binding Domain In order to determine whether the putative ET-I binding domain, as delineated by the homology to antisense peptide sequences (Fig. 1) , indeed represents the structural determinants for ET-1 binding within the ET-I /AngII receptor, we performed mutational studies on the putative ET-I 
Discussion
The elucidation of the ET-i/AngII receptor as a single transmembrane domain receptor is unique among AngIl (1 1,23-27) and ET (28) (29) (30) seventransmembrane domain G-protein-coupled receptors. The dual ET-i/AngH receptor is functionally coupled to a Ca2+-mobilizing transduction system, responding equivalently to both ET-I and AnglI in a highly specific manner. The ET-I and AngII EC50 values of 7 pmol/L and 6 pmol/L, respectively, strongly suggest that this receptor is fully functional under normal physiological conditions as their respective EC50 values fall well within the range of normal circulating levels of respective peptide hormones (31, 32) . Interestingly, Sarl -Ala8-AngII (AnglIspecific antagonist) blocked both the AngII-and ET-I-induced Ca2+ response (Fig. 2B) . The molecular mechanism involved in the inhibition of the ET-1 response by the AngII-specific inhibitor, Sarl-Ala8-AngII, most likely involves inhibition of ET-I-induced receptor conformational transition necessary to activate the downstream transducing system effected by ET-1 since neither AnglI (Fig. 2E) nor Sarl-Ala8-AngII (data not shown) were able to displace 1251-ET-I-specific binding.
ET-I and AngIl can evoke a number of similar responses in different organ systems (33) . The existence of the dual ET-i /AngII receptor could partially explain these observations. Recently, it has been reported that both ET-1 and AngIl stimulated fibronectin and type IV collagen mRNA expression and mitogenesis in rat mesangial cells (34) . Unexpectedly, Losartan (a specific AT1 receptor antagonist) inhibited the ET-i-mediated effects whereas BQ-123 (a specific ETA receptor antagonist) inhibited the AngII-induced fibronectin synthesis and mesangial cell proliferation (34) . These data could well be explained by the presence and mediation of these physiologic responses by the ET-I /AngII receptor in rat mesangial cells. The inhibition of ET-I -mediated responses by Losartan (34) resembles the inhibition of ET-I-induced Ca21 mobilization by SarlAla8-AngII noted above (Fig. 2B) . We have detected ET-i /AngII receptor mRNA in kidney; however, its existence in mesangial cells remains to be determined.
Our results demonstrate that the motif E60MKSRWNW67 is necessary for ET-I binding to the ET-i /AngII receptor. This is in contrast with previous structure-functional studies in which extensive regions within endothelin receptors spanning extracellular, transmembrane, and intracellular portions of the receptor have been invoked to be involved in endothelin binding (35) (36) (37) . These studies, however, did not exclude the possibility of conformational effects induced by the mutagenic changes because of the lack of "internal control" that could account for induced conformational/allosteric effects. It is interesting to note that the antisense peptide delineating the ET-1 binding domain encompasses the carboxyl-terminal 8 amino acids of the ET-1 peptide, thus indicating that these 8 residues most likely represent the motif within ET-1 that interact with the ET-i /AngII receptor. This is consistent with previous observations implicating the carboxyl-terminal domain of endothelin peptides in their binding to their corresponding receptors (38) (39) (40) , respectively.
The isolation and characterization of the ET-1 /AngII receptor elucidates a new paradigm involved in the evolution of hormone-binding domains in different receptors, thus refining a principle of the molecular recognition theory. The data presented above identified the antisense peptides from frames 2 and 3 as the related evolutionary precursor binding domains for and AngII, respectively, in the ET-I /AngII receptor (Fig. 1) . On the other hand, the antisense peptides in frame 1 for both AngII and AVP were delineated as the corresponding precursor binding domains within the AngII/AVP receptor (1 ). These findings suggest that antisense peptides originating from the three possible frames can be used as potential precursor binding domains in the evolutionary pathway of different isoreceptors. This intrinsic property of derived antisense peptides probably had a significant impact in the evolution of peptide hormone-cognate receptor systems by effectively increasing the possibility of producing putative cognate receptors. We anticipate that as more molecular genetic, physicochemical, and crystallographic evidence accumulates in the near future, a more complete understanding of the evolution and principles underlying peptide and protein-protein interaction will emerge, thus opening a window into a fundamental organizational principle that governs structure and function in living cells.
